Mouse Anti-MYO5B (AA 940-1051) Recombinant Antibody (CBFYM-2991) (CBMAB-M3186-FY)

Name: Mouse Anti-MYO5B (AA 940-1051) Recombinant Antibody (CBFYM-2991)
SKU: CBMAB-M3186-FY
Rating: 5 (1 reviews)

See all MYO5B antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBFYM-2991

Application

Immunogen

Rat Myr6 aa. 940-1051

Specificity

Rat

Antibody Isotype

IgG1

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Concentration

0.25 mg/mL

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Epitope

AA 940-1051

More Infomation

Target

Full Name

MYOSIN VB

Introduction

The protein encoded by this gene, together with other proteins, may be involved in plasma membrane recycling. Mutations in this gene are associated with microvillous inclusion disease.

Entrez Gene ID

25132

UniProt ID

P70569

Alternative Names

Myosin VB; Unconventional Myosin-Vb; MYO5B Variant Protein; Myosin-Vb; KIAA1119

Function

May be involved in vesicular trafficking via its association with the CART complex. The CART complex is necessary for efficient transferrin receptor recycling but not for EGFR degradation. Required in a complex with RAB11A and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane. Together with RAB11A participates in CFTR trafficking to the plasma membrane and TF (transferrin) recycling in nonpolarized cells. Together with RAB11A and RAB8A participates in epithelial cell polarization. Together with RAB25 regulates transcytosis.

Biological Process

Actin filament organization Source: GO_Central
Endosomal transport Source: UniProtKB
Protein transport Source: UniProtKB-KW
Renal water homeostasis Source: Reactome
Vesicle-mediated transport Source: UniProtKB
Vesicle transport along actin filament Source: GO_Central

Cellular Location

Cytoplasm

Involvement in disease

Diarrhea 2, with microvillus atrophy (DIAR2):
A disease characterized by onset of intractable life-threatening watery diarrhea during infancy. Two forms are recognized: early-onset microvillus inclusion disease with diarrhea beginning in the neonatal period, and late-onset, with first symptoms appearing after 3 or 4 months of life.

Vij, M., & Shah, V. (2022). Compound heterozygous myosin 5B (Myo5b) mutation with early onset progressive cholestasis and no intestinal failure. Fetal and Pediatric Pathology, 41(5), 811-817.

Bowman, D. M., Kaji, I., & Goldenring, J. R. (2022). Altered MYO5B Function Underlies Microvillus Inclusion Disease: Opportunities for Intervention at a Cellular Level. Cellular and Molecular Gastroenterology and Hepatology, 14(3), 553-565.

Wang, L., Qiu, Y. L., Xu, H. M., Zhu, J., Li, S. J., OuYang, W. X., ... & Wang, J. S. (2022). MYO5B‐associated diseases: Novel liver‐related variants and genotype‐phenotype correlation. Liver International, 42(2), 402-411.

Li, Q., Zhou, Z., Sun, Y., Sun, C., Klappe, K., & van IJzendoorn, S. C. (2022). A functional relationship between UNC45A and MYO5B connects two rare diseases with shared enteropathy. Cellular and molecular gastroenterology and hepatology, 14(2), 295-310.

Kaji, I., Roland, J. T., Rathan-Kumar, S., Engevik, A. C., Burman, A., Goldstein, A. E., ... & Goldenring, J. R. (2021). Cell differentiation is disrupted by MYO5B loss through Wnt/Notch imbalance. JCI insight, 6(16).

Aldrian, D., Vogel, G. F., Frey, T. K., Ayyıldız Civan, H., Aksu, A. Ü., Avitzur, Y., ... & Janecke, A. R. (2021). Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with MYO5B mutations. Journal of Clinical Medicine, 10(3), 481.

Overeem, A. W., Li, Q., Qiu, Y. L., Cartón‐García, F., Leng, C., Klappe, K., ... & van Ijzendoorn, S. C. (2020). A molecular mechanism underlying genotype‐specific intrahepatic cholestasis resulting from MYO5B mutations. Hepatology, 72(1), 213-229.

Tomić, T. T., Olausson, J., Rehammar, A., Deland, L., Muth, A., Ejeskär, K., ... & Abel, F. (2020). MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression. PLoS genetics, 16(6), e1008803.

Leng, C., Overeem, A. W., Cartón-Garcia, F., Li, Q., Klappe, K., Kuipers, J., ... & van IJzendoorn, S. C. (2019). Loss of MYO5B expression deregulates late endosome size which hinders mitotic spindle orientation. PLoS biology, 17(11), e3000531.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-MYO5B (AA 940-1051) Recombinant Antibody (CBFYM-2991)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry